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Abstract: Hepatocellular carcinoma (HCC) is the third main cause of cancer-related death. Cyclin-dependent kinases (CDKs) and their
cyclin partners regulate the cell cycle. Since inhibition of CDKs gives some guiding ideas for cancer studies, we aimed to determine the
possible effects of R547, a cyclin kinase 1-2-4 inhibitor, on proliferation and apoptotic mechanisms of Hep G2 cells (human) and H-4II-E cells derived from rat HCC. We determined in vitro survival rates with MTT assay, apoptosis with flow cytometry, morphological
changes with confocal microscopy, and ultrastructural changes by transmission electron microscopy. Cisplatin was used as a positive
control. After 24 h of culture with 0.1, 1, 10, 50, and 100 µM doses of R547, the corresponding percentages of live Hep G2 cells were
101%, 94%, 93%, 89%, and 79% (P < 0.001), respectively. However, with the same R547 doses the live Hep G2 cell percentages were
92%, 101%, 53.6% (P <0 .01), 47.4% (P < 0.001), and 41% (P < 0.001), respectively, after 48 h. After 24 h of incubation with the same
doses of R547, the survival percentages of live rat cells were 90%, 80% (P < 0.01), 63% (P < 0.001), 47% (P < 0.001), and 43% (P < 0.001),
respectively. The percentages of surviving H-4-II-E cells were 96%, 85% (P < 0.01), 46% (P < 0.001), 44% (P < 0.001), and 45% (P <
0.01), respectively, after 48 h. Since R547 did not significantly affect Hep G2 cell survival in 24 h, experiments of apoptosis were carried
out with H-4-II-E cells. The early apoptotic rates of 38% and 45% (P < 0.05 for both) after applications of 10 and 25 μM R547 (control:
4.1%), respectively, indicated that R547 has an apoptotic effect on H-4-II-E cells in 24 h. The apoptosis morphology at 24 h of treatment
was clearly observed with microscopic examinations. According to our results, it is obvious that R547 has antiproliferative action when
compared to cisplatin.
Key words: R547, hepatocellular carcinoma, Hep G2, H-4-II-E, apoptosis, flow cytometry, microscopy

1. Introduction
Hepatocellular carcinoma (HCC) is one of the most
common types of cancer that originates from hepatocytes.
It is more common in males over the age of 50 than
females. Approximately 80% of patients with HCC are of
Asian or African origin. The risk factors for HCC include
chronic viral hepatitis B and hepatitis C infections, alcohol
addiction, usage of tobacco and tobacco products, and
aflatoxin. The lack of symptoms during HCC makes
the diagnosis difficult. Since it is an aggressive tumor,
the survival period of patients is only a few years. For
approximately 70% of patients with HCC, this period is
about 5 years (Wang et al., 2012). Treatment of the disease
depends on tumor size and stage, and high-grade tumors
result in poor prognosis. Surgery is one of the main
treatment methods for HCC; on the other hand, nowadays,
liver transplantation is the most effective method (Zhang et
al., 2007). The suitability of surgical treatment for patients

with HCC is about 20% (Zhang et al., 2012). Radiotherapy
and chemotherapy are also treatment options that do not
give good expected results. Chemotherapy and the effects
of the drugs used are typically limited due to hepatic
and systemic toxicities. These agents expose patients to
various side effects when causing HCC cell death (Kang et
al., 2010). Since HCC needs more effective and less toxic
drugs, the discovery of new anticancer drugs that stimulate
apoptosis is promising.
The cell cycle in multicellular organisms is very
important for proliferation, growth, wound healing, and
many other biochemical and physiological processes
(Funk, 2005). Cyclin-dependent kinases (CDKs) are
members of the serine/threonine protein kinase family.
They have very important roles in cell cycle regulation
and transcription (Sanchez-Martinez et al., 2015). At the
G1 phase of the cell cycle, the CDK4/cyclin D and CDK6/
cyclin D complexes regulate the termination of the cycle
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according to the cell signaling, cellular activities, growth
and development, and maintenance of homeostasis in
eukaryotic cells through the phosphorylation mechanism.
The S phase starts with the CDK2/cyclin A complex, and
the CDK1/cyclin B complex regulates the G2 phase and
the beginning of the mitotic phase (Shackelford, 1999;
Peyressatre, 2015).
Apoptosis has become a focal point of hope for the
treatment of diseases via the apoptotic mechanism.
Apoptosis is generally known as type I programmed
cell death that is characterized by cell shrinkage, DNA
concentration, fragmentation, membrane blebbing,
depolymerization of the cell skeleton, and apoptotic
body formation. It shows caspase activation along death
receptors or mitochondrial pathways (Xu et al., 2014).
Proliferation and death mechanisms in cells have a certain
balance and harmony.
Since R547 inhibits the CDK1/cyclin B, CDK2/cyclin
E, and CDK4/cyclin D1 complexes, the cell cycle is stopped
at the transition of the G1 and G2 phases. It is known that
it reduces the phosphorylation of retinoblastoma (RB)
protein by using the RB pathway, stimulates apoptosis,
and causes cancer cell death. It is believed that R547 is
a promising molecule for solid tumor treatment during
phase I studies in vitro and in vivo in various human
tumor xenograft models (De Pinto et al., 2006). Since HCC
requires more effective and less toxic treatments, we aimed
to reveal the effect of R547, a CDK inhibitor in HCC,
which has not yet been elucidated. Based on all of this
information, we intended to examine an ATP-competitive
CDK inhibitor, R547, at various time and dose intervals on
the growth and apoptosis of two HCC cell lines.
2. Materials and methods
2.1. Cell culture and groups
We used human HCC cell line Hep G2 and rat HCC
cell line H-4-II-E (ATCC). The cell lines were fed with
a mixture of 10% fetal calf serum (FCS), 1% penicillinstreptomycin, and 89% Dulbecco’s modified Eagle’s
medium (DMEM, Sigma-Aldrich) in an incubator that
had 37 °C temperature, 5% CO2, and 95% O2 hyperoxide
conditions (Oztopcu-Vatan et al., 2015). Both cell lines
were treated with 0.1, 1, 10, 50, and 100 µM doses of R547
(Cayman) for 24 h and 48 h. DMSO was used as a vehicle.
As a positive control, cisplatin (Sigma-Aldrich) at doses of
5, 10, 25, 50, and 100 µM was applied to both cell lines for
24 and 48 h. The control groups contained only feeding
medium.
2.2. Cell survival analysis
After numbers of cells were determined with the trypan blue
method by using a CEDEX cell counter (Roche Diagnostics
International Ltd.), 1 × 104 cells were plated in each well
of 96-well plates. R547 and cisplatin as mentioned above

were added for 24 and 48 h by appropriate calculations
and each experiment was repeated at least three times.
After 24 and 48 h of treatments, survival rates of the cells
were determined by 3-[4,5-dimethylthiazol-2yl]-diphenyl
tetrazolium bromide (MTT) method (Mossmann, 1983).
The optical density was read by a spectrophotometer
(BioTek Instruments) at 550 nm wavelength and converted
to percentage of living cells according to control cells. The
formula is as follows:
(Cell absorbance of the drug in each well × 100) /
Absorbance of control cells
2.3. Analyzing apoptosis by flow cytometry
Since according to MTT results, the inhibitory effect of
R547 was marked only at the higher doses for 24 h, it was
decided not to use the Hep G2 cell line in the following
experiments.
Accordingly, 1 × 106 H-4-II-E cells were plated in 252
cm flasks with doses of 10 and 50 µM R547 or DMSO and
incubated for 24 h. The cells were then removed with 0.25%
trypsin-EDTA solution (Sigma-Aldrich). The number
of cells in 1 mL was determined by trypan blue method.
The cell solution was adjusted with binding buffer to be 1
× 106 cells in number according to the kit’s instructions.
H-4-II-E cells, treated or not treated with 10 or 50 μM
R547 or DMSO for 24 h, were stained with the FITC
Annexin V Apoptosis Assay Kit with propidium iodide
(PI, Invitrogen), and then 5 µL of FITC-annexin V, 10 µL
of PI, and 100 µL of cell solutions were added carefully into
2-mL vials. The vials were incubated for 15 min in the dark
at room temperature, allowing them to mix thoroughly
and precisely. After incubation, 400 µL of the annexin V
binding solution was added to the vials. These stages of
the study were carried out by flow cytometry (Acury BD)
in the Pharmaceutical Microbiology Laboratory of the
Faculty of Pharmacy at Anadolu University, Eskişehir,
Turkey. All experiments were repeated three times.
2.4. Observing the morphological changes with confocal
microscopy
About 150,000 H-4-II-E cells were seeded in each well of
6-well plates in 5 mL of medium and incubated for 24 h
for analyzing possible morphological changes caused by
R547. After the incubation period, 10 or 50 µM doses
of R547 were applied to each well for 24 h. The medium
was removed and cells were washed with cold phosphate
buffered saline solution (PBS) and then fixed with 2.5%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). After
fixation, the cells were washed again with cold PBS and
dyed with 0.1 mg/mL acridine orange and Alexa Fluor
488 Phalloidin. Morphological changes that occurred
in the cells were examined by a Leica SP5 laser scanning
confocal microscope and photographs were taken at the
Plant, Drug, and Scientific Research Center (BİBAM) of
Anadolu University, Eskişehir, Turkey.
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2.5. Examining ultrastructural changes by transmission
electron microscopy (TEM)
To ensure morphological changes in H-4-II-E cells, 1 × 106
cells were seeded in each 25-cm2 flask. After the incubation
period of 24 h, the control group was fed with only 5 mL of
medium, and the 10 and 50 µM R547 groups were fed with 5
mL of medium containing the calculated doses of drug and
incubated for an additional 24 h. Then the cells were fixed
with 2.5% glutaraldehyde for 4 to 24 h at 4 °C. The second
fixation in 2% osmium tetroxide was performed to link the
unit membrane lipid layers and proteins. Dehydration was
achieved by passing through a series of 50%, 70%, 90%, and
96% pure ethanol (100%). The cells were then embedded
in EPON 812 epoxy. As a final step, the cells were freshly
prepared and placed in a recessed medium and allowed to
block for 48 h. When the blocks were ready, the sections
were stained with a solution containing heavy metal salts
such as uranyl acetate and lead acetate for enhancement
and staining. After staining, the sections were rolled on
porous or film-coated conductive copper sheets or grids.
Morphological changes were examined by using TEM (FEI
Bio Tween) at BİBAM.
2.6. Statistics
The results of MTT assays were analyzed using one-way
analysis of variance and then Tukey’s multiple comparison
test by using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). P
< 0.05 was considered significant. For evaluating the
results of flow cytometry analysis, normalization tests
and nonparametric Kruskal–Wallis tests were performed.
The results of apoptosis were analyzed by Kolmogorov–
Smirnov normality test and then nonparametric Kruskal–
Wallis test by using SPSS 16.0 for statistical evaluation

of vitality, apoptosis, and death values of the cells after
R547 treatments. The apoptotic results are presented as
percentages of cells.
3. Results
3.1. Analyzing cell survival by MTT assay
The percentages of living Hep G2 cells treated with R547 at
doses of 0.1, 1, 10, 50, and 100 µM for 24 h were found as
101%, 94%, 93%, 89%, and 79% (P < 0.001), respectively.
Survival rates of Hep G2 cells treated with the same doses
for 48 h were 92%, 101%, 53.6% (P < 0.01), 47.4%, and 41%
(P < 0.001), respectively. The IC50 inhibition concentration
of R547 for Hep G2 cells was 88 μM for 48 h. There was
no change in the survival rates of both cell lines with the
highest concentration of DMSO. According to MTT
results, the inhibitory effect of R547 was marked only at
the highest dose of R547 for 24 h and so it was decided not
to use the Hep G2 cell line in the following experiments
(Figure 1).
When H-4-II-E cells were treated with the above doses
of R547 for 24 h, the percentages of surviving cells were
90%, 80% (P < 0.01), 63%, 47%, and 43% (P < 0.001),
respectively. The survival rates of H-4-II-E cells treated
with the same R547 doses for 48 h were 96%, 85% (P <
0.01), 46%, 44%, and 45% (P < 0.001), respectively. The IC50
inhibition concentration of R547 for H-4-II-E cells was 66
μM for 24 h, while it was 23 μM for 48 h. Depending on
the percentage of cell death rates obtained from 24 and 48
h of treatments, we decided to study H-4-II-E cells for the
apoptosis investigation (Figure 2).
Cisplatin at 5, 10, 25, 50, and 100 µM was used for a
positive control for 24 and 48 h for both cell lines. The
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Figure 1. The effect of R547 on Hep G2 cell survival for 24 and 48 h (**: P <0.01
and ***: P <0.001).
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3.3. Analyzing the morphological changes by confocal
microscopy
H-4-II-E cells, treated with 10 or 50 µM R547 for 24 h, were
examined under a confocal microscope and compared
with the control. Membranes, nucleus structures, and
skeleton structures of the cells were found to be normal
in the control group. The cells retained their polygonal
structure in their normal state (Figures 6a and 6b).
In the 10 µM R547 group, the cells lost their
morphological integrity. Blebbing and holes occurred as a
result of defects in the membranes and skeletons of the cells.
The normal structure of the chromosomes was disrupted
and fragmented. The cell membrane deformation caused
by the outward opening of the cell skeleton with budding

living Hep G2 cells after 24 h of incubation were calculated
as 108%, 109%, 107%, 99%, and 96%, respectively, and for
48 h as 100%, 101%, 93%, 85.5% (P < 0.001), and 81 (P
< 0.001) , respectively. When treated with the same doses
of cisplatin for 24 h, the percentages of live H-4-II-E cells
were calculated as 95%, 87% (P < 0.001), 76% (P < 0.001),
71% (P < 0.001), and 70% (P < 0.001), respectively, and
after 48 h as 96%, 82% (P < 0.01), 60% (P < 0.001), 61% (P
< 0.001), and 56% (P < 0.001; Figures 3 and 4).
3.2. Results of flow cytometry
The percentages of apoptotic cells were 4.07% in the
control group, 2.57% in the DMSO group, 37.8% in the
10 µM R547 group, and 45.4% in the 50 µM R547 group
(Figure 5; Table).
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Figure 2. The effects of R547 on H-4-II-E cell viability.
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Figure 3. Influence of cisplatin on Hep G2 cell viability.
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Figure 4. Cisplatin’s effect on H-4-II-E cell survival.

out of the cell indicates apoptosis. The structural defects
were indicated by circles and squares (Figures 7a and 7b).
In the 50 µM R547 group, the cells were diminished
by losing their morphological structures. Blebbing and
holes occurred as a result of defects in the cell membrane
and skeleton. Normal structure of the chromosomes was
disrupted and fragmented, DNA fractures occurred, and
apoptotic body formations were observed. The structural
defects were indicated by squares and circles (Figures 8a
and 8b).
3.4. Studying the ultrastructural changes by TEM
In the control group, normal cell membrane, shape,
and nucleus were observed and the chromosomes were
collected in the nucleus (Figures 9a and 9b).
The cell membrane was disrupted and the cell content
was dispersed. Along with the deformation of the cell nuclei,
chromosomes were concentrated in the 10 µM R547 group.
In addition, myelinated sheath formation and autophagic
vacuole formation were observed. The structural defects
were indicated by arrows (Figures 10a and 10b).
The structure and content of the cells, mitochondria,
and nuclei were impaired in the 50 µM R547 group. The
horseshoe shape of the nucleus may suggest that apoptosis
occurred (Figure 11a). In addition, the mitochondria were
swollen and the contents of the cavities were discharged,
and an increase in vacuolization and the deformation of
mitochondria were observed with an intense metabolic
increase in the cells (Figure 11b). The resulting structural
defects were indicated by arrows.
4. Discussion
In the present study, R547 caused only 21% of Hep G2 cell
death at the highest dose in 24 h, but it caused 52% and
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59% cell death at 50 and 100 µM in 48 h. R547 had greater
decreasing efficacy on H-4-II-E cell viability in both 24 and
48 h, as shown in Figure 2. Similarly, in the study by De
Pinto et al. (2006), the antiproliferative effects of R547 were
examined by MTT assay in colon, breast, lung, prostate,
cervix, melanoma, B-cell lymphoma, and osteosarcoma
cell lines. Their results indicated that R547 has potent in
vitro antiproliferative effects (IC50: approximately 0.05–0.6
µmol/L) on all these cell lines. They also showed that the
growth-inhibitory activity is characterized by a cell cycle
block at the G1 and G2 phases. In addition, they found
that R547 stimulates apoptosis. Additionally, in very recent
research, AZD5438 and R547, which are cyclin-dependent
kinase inhibitors, showed potential for enhancing the
efficacy of daunorubicin-based anticancer therapy (Sorf et
al., 2019). Cisplatin is a drug used in chemotherapy during
the treatment of various types of cancer by inhibiting
DNA synthesis and killing cancer cells (Kishimoto et al.,
2016). Also, it was shown that cisplatin, which is used as a
positive control, has a weaker effect on viability of Hep G2
and H-4-II-E cells compared to the effect of R547 (Figures
3 and 4). Supporting our results, Kishimoto et al. (2016)
did not find any significant effect on cell viability when
they treated H-4-II-E and Hep G2 cells with doses of 0.1,
1, and 10 µM cisplatin for 72 h.
In this study, because R547 had less effect on cell
numbers and decreasing activity in Hep-G2 cells in 24 h,
we continued the research about apoptosis with rat H-4II-E cells. We chose 10 and 50 μM doses of R547 because
these two doses had the most antiproliferative effects
on rat H-4-II-E cells in 24 h. We determined that R547
induces apoptosis of HCC cells dose-dependently in vitro.
The percentages of early apoptotic values at 10 and 50 μM

HACIOĞLU et al. / Turk J Biol

Figure 5. Typical quadrant analysis of annexin V-FITC/PI flow cytometry of H-4-II-E cells that were treated for 24 h with
two higher doses of R547 (10 and 50 µM) and DMSO.
Table. Proportions of viable, early apoptotic, and late apoptotic/necrotic cells
after exposure to 10 and 50 µM doses of R547 or DMSO for 24 h in H-4-II-E
cells. *: P < 0.05. The data are expressed as the mean ± SD of the mean. The
results are the means of three experiments.
Group

Viable (%)

Early apoptotic (%)

Late apoptotic (%)

Control

92.93 ± 1.51

4.07 ± 0.06

3.20 ± 1.21

DMSO

94.83 ± 1.46

2.57 ± 0.93

2.13 ± 0.51

10 µM

47.03 ± 8.82*

37.80 ± 4.11*

14.87 ± 4.91*

50 µM

45.20 ± 4.20*

45.40 ± 5.86*

9.27 ± 1.72*
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a)

µm

b)

Figure 6. a and b) Confocal microscopic images of the control group of H-4-II-E cells.

a)

b)

Figure 7. a and b) Confocal microscopic views of 10 µM R547 group. Due to the deformation of the membrane and cell skeleton
of the cells, holes that formed in the cell skeleton with budding were observed. Additionally, chromosome degradation was
observed in the cell nucleus. The resulting structural defects were indicated by arrows.

were about 38% and 46% for R547, respectively, for 24 h
(Table). Our confocal and TEM examinations revealed
morphological changes of the cells caused by apoptosis. We
observed cell content deterioration, cell shrinkage, DNA
fragmentation, cell membrane budding, apoptotic body
formation, core condensation, and horseshoe nucleation.
It is known that condensation of chromatin and DNA
fragmentation are indicators for the determination of
apoptosis with TEM (Doonan and Cotter, 2008). There
are several studies showing that CDK inhibitors induce
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apoptosis. For example, Xiao et al. (2014) used paclitaxel
for the treatment of malignant tumors, followed by
RO3306, which is a CDK1 inhibitor, both separately and
in combination on the Hep G2 cell line. They applied
paclitaxel at a 0.2 µM dose for 18 h followed by RO3306
at 2 µM for 6 h. According to their study, these two drugs
used in combination provided a synergetic inhibition on
the cells, moving the cells from mitosis to apoptosis. In
another study conducted by Shi et al. (2015), fluspirilene,
which is a potential CDK2 inhibitor and is used as an

HACIOĞLU et al. / Turk J Biol

a)

b)

Figure 8. a and b) Confocal microscopic illustrations of 50 µM R547 group. Deformation budding and density of apoptotic
bodies in the cell membrane were observed. In addition, hole formation in the cell skeleton and chromosomal deformations in
the nucleus were observed. The resulting structural defects are indicated by arrows (a). DNA fragmentation and DNA fractures
are shown by circle (b).

a)

b)

Figure 9. a and b) TEM views of untreated H-4-II-E cells. Hexagon shows normal cell shape (a). Arrows indicate normal cell
membrane, shape, and nucleus (b).

antipsychotic drug, stopped Hep G2 and human HCC
cell division in the G1 and S phases depending on dose
and time. It revealed changes in CDK2 levels and induced
apoptosis. They suggested that fluspirilene can be used
in various types of cancer treatments. In another in vitro
study, Bollard et al. (2017) mentioned that when used alone
or in combination with sorafenib, pablociclib, a CDK4 and

CDK6 inhibitor, suppressed proliferation in Hep G2 and
other human HCC cell lines depending on dose and time.
Zhang et al. (2012) indicated that dihydroartemisinin
(DHA), another CDK inhibitor, decreased cell viability by
50% at a dose of 20 µM in 24 h depending on dose. Cho
et al. (2010) determined that apoptosis in Hep G2 and
different HCC cells was induced via increases in caspase
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a)

b)

Figure 10. a and b) Photographs of 10 µM R547 group cells from TEM. The cell nucleus was seen to have disappeared.
Myelinated sheath formation and autophagic vacuole formation were observed (a). In addition, chromosomes were densified
with deformation of the cell nucleus (b).The resulting structural defects were indicated by arrows.

a)

b)

Figure 11. a and b) Structural views of 50 µM R547 group cells from TEM. The cell membrane was deformed and the nucleus
of the cell took the shape of a horseshoe. In addition, the mitochondria were swollen and their crystals dispersed (a). Arrows
indicate thin and long mitochondria (b).

3 and caspase 9 activation after treatment with 10 and 50
µM doses of xylocydine, a specific CDK inhibitor, for 24
h. Moreover, De Pinto et al. (2006) examined the effects
of treatment with R547 on DNA fragmentation. They
confirmed that R547 induces apoptosis as measured by
DNA fragmentation. All of these indicated results support
our findings.
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In conclusion, R547 inhibited proliferation of Hep G2
cells at 48 h and H-4-II-E cells at both 24 and 48 h. The
same inhibitor caused apoptosis with morphological and
ultrastructural changes in H-4-II-E cells in 24 h. Therefore,
R547 may have a promising role against HCC as an inhibitor of
CDK and an apoptosis-inducing candidate. Further studies are
needed to clearly understand the mechanism of R547’s action.
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